Table 3 Comparison of c-index between the survival path system, BCLC staging system, and AJCC staging system in the internal testing cohort and multicenter testing cohort

From: Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data

Time slice

Number (modeling/all)

Survival path system

BCLC staging system

AJCC staging system

Number of nodes

c-Index (95% CI)

Number of classes

c-Index (95% CI)

Number of classes

c-Index (95% CI)

Internal testing cohort

 

 No.1

627/627

2

0.634 (0.632–0.636)

1

6

0.634 (0.632–0.636)

 No.2

562/562

4

0.695 (0.692–0.698)

5

0.724a (0.721–0.727)

6

0.733a (0.730–0.736)

 No.3

367/367

8

0.747 (0.722–0.752)

4

0.729b (0.725–0.733)

6

0.737b (0.732–0.742)

 No.4

271/277

10

0.774 (0.766–0.782)

4

0.751b (0.743–0.759)

6

0.737b (0.729–0.745)

 No.5

210/222

11

0.764 (0.755–0.773)

4

0.760 (0.749–0.771)

6

0.728b (0.712–0.739)

 No.6

171/181

11

0.756 (0.743–0.769)

5

0.785a (0.755–0.775)

6

0.746 (0.732–0.760)

 No.7

125/148

8

0.820 (0.803–0.837)

4

0.817 (0.801–0.833)

6

0.824 (0.808–0.840)

Multicenter testing cohort

 

 No.1

414/414

2

0.631 (0.628–0.634)

1

3

0.602b (0.599–0.605)

 No.2

359/359

4

0.689 (0.685–0.693)

4

0.698a (0.694–0.702)

6

0.715a (0.711–0.719)

 No.3

233/234

7

0.725 (0.718–0.732)

4

0.715 (0.709–0.721)

6

0.720 (0.714–0.726)

 No.4

181/189

8

0.790 (0.781–0.799)

4

0.752b (0.742–0.762)

6

0.759b (0.749–0.769)

 No.5

131/149

7

0.778 (0.765–0.791)

4

0.757b (0.745–0.769)

6

0.754b (0.743–0.765)

 No.6

113/128

7

0.769 (0.750–0.788)

4

0.714b (0.695–0.733)

6

0.734 (0.716–0.752)

  1. aThe c-index of the interested system was higher than the survival path system, with P < 0.006
  2. bThe c-index of the interested system was lower than the survival path system, with P  < 0.006